Comparison
NMN vs Memantine (Namenda)
NMN
Nicotinamide mononucleotide, NAD+ precursor. Studied for cellular aging and metabolic health.
Memantine (Namenda)
Prescription NMDA receptor antagonist for moderate-to-severe Alzheimer's disease. Reduces glutamate excitotoxicity while preserving normal signaling.
| Field | NMN | Memantine (Namenda) |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 250–1000mg | 5–20mg |
| Half-life | – | 70h |
| Onset | – | 180min |
| Evidence | EVIDENCEB | EVIDENCEA |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USRx |
| PubMed refs | 600 | 4200 |
The comparison in plain English
Auto-generated from dataNMN and Memantine (Namenda) are both in the neuroprotective category respectively. NMN Nicotinamide mononucleotide, NAD+ precursor. Memantine (Namenda) Prescription NMDA receptor antagonist for moderate-to-severe Alzheimer's disease.
Bottom line
NMN (evidence B, safety 5/5) has a stronger evidence base than Memantine (Namenda) (evidence A, safety 4/5). NMN has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose NMN if
NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+, one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is –h.
Choose Memantine (Namenda) if
Memantine (Namenda) is the better fit when your goal aligns with its mechanism (Uncompetitive NMDA receptor antagonist, blocks the NMDA channel only when it's pathologically over-activated, sparing normal signaling) and the dose range (5–20mg) suits your protocol. Half-life is 70h.